SG11201809672YA - Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives - Google Patents
Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole DerivativesInfo
- Publication number
- SG11201809672YA SG11201809672YA SG11201809672YA SG11201809672YA SG11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxyalkyl
- preparing
- triazole derivatives
- phenyl
- substituted
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- CGRLXLHYYDSTKR-UHFFFAOYSA-N 1-phenyl-1H-1,2,4-triazole Chemical class N1=CN=CN1C1=CC=CC=C1 CGRLXLHYYDSTKR-UHFFFAOYSA-N 0.000 title abstract 2
- -1 monofluoromethyl Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168165 | 2016-05-03 | ||
| EP16168163 | 2016-05-03 | ||
| EP16168166 | 2016-05-03 | ||
| EP16168169 | 2016-05-03 | ||
| EP16168172 | 2016-05-03 | ||
| EP17160086 | 2017-03-09 | ||
| PCT/EP2017/060367 WO2017191104A1 (de) | 2016-05-03 | 2017-05-02 | Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809672YA true SG11201809672YA (en) | 2018-11-29 |
Family
ID=58633014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809672YA SG11201809672YA (en) | 2016-05-03 | 2017-05-02 | Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10703742B2 (OSRAM) |
| EP (1) | EP3452467A1 (OSRAM) |
| JP (2) | JP6921863B2 (OSRAM) |
| KR (1) | KR20190003536A (OSRAM) |
| CN (2) | CN113105403A (OSRAM) |
| AU (2) | AU2017259872B2 (OSRAM) |
| BR (1) | BR112018072528A2 (OSRAM) |
| CA (1) | CA3022789A1 (OSRAM) |
| CL (1) | CL2018003107A1 (OSRAM) |
| CO (1) | CO2018011948A2 (OSRAM) |
| IL (1) | IL262534B (OSRAM) |
| MX (2) | MX391356B (OSRAM) |
| PE (1) | PE20190202A1 (OSRAM) |
| RU (1) | RU2742885C2 (OSRAM) |
| SG (1) | SG11201809672YA (OSRAM) |
| TW (1) | TWI755393B (OSRAM) |
| UY (1) | UY37222A (OSRAM) |
| WO (1) | WO2017191104A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071464A (zh) * | 2016-05-03 | 2018-12-21 | 拜耳制药股份公司 | 氧代烷基取代的苯基三唑衍生物及其用途 |
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| CN113105403A (zh) * | 2016-05-03 | 2021-07-13 | 拜耳制药股份公司 | 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法 |
| WO2021259852A1 (en) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI490212B (zh) * | 2006-05-25 | 2015-07-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性之三唑化合物 |
| EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| JP5826773B2 (ja) | 2010-02-27 | 2015-12-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ビスアリール−結合アリールトリアゾロン及びその用途 |
| AU2013258107B2 (en) * | 2012-05-08 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Method for the preparation of triazole compounds |
| PE20170945A1 (es) | 2014-11-03 | 2017-07-13 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
| CN109071464A (zh) * | 2016-05-03 | 2018-12-21 | 拜耳制药股份公司 | 氧代烷基取代的苯基三唑衍生物及其用途 |
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| CN113105403A (zh) * | 2016-05-03 | 2021-07-13 | 拜耳制药股份公司 | 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法 |
-
2017
- 2017-05-02 CN CN202110424553.XA patent/CN113105403A/zh active Pending
- 2017-05-02 BR BR112018072528-5A patent/BR112018072528A2/pt active Search and Examination
- 2017-05-02 MX MX2020010365A patent/MX391356B/es unknown
- 2017-05-02 KR KR1020187031568A patent/KR20190003536A/ko not_active Ceased
- 2017-05-02 CN CN201780027607.0A patent/CN109071500B/zh not_active Expired - Fee Related
- 2017-05-02 RU RU2018142264A patent/RU2742885C2/ru active
- 2017-05-02 EP EP17719636.7A patent/EP3452467A1/de not_active Withdrawn
- 2017-05-02 AU AU2017259872A patent/AU2017259872B2/en not_active Ceased
- 2017-05-02 PE PE2018002254A patent/PE20190202A1/es unknown
- 2017-05-02 UY UY0001037222A patent/UY37222A/es not_active Application Discontinuation
- 2017-05-02 US US16/098,238 patent/US10703742B2/en not_active Expired - Fee Related
- 2017-05-02 MX MX2018013336A patent/MX379555B/es unknown
- 2017-05-02 SG SG11201809672YA patent/SG11201809672YA/en unknown
- 2017-05-02 CA CA3022789A patent/CA3022789A1/en active Pending
- 2017-05-02 JP JP2018557408A patent/JP6921863B2/ja not_active Expired - Fee Related
- 2017-05-02 TW TW106114435A patent/TWI755393B/zh not_active IP Right Cessation
- 2017-05-02 WO PCT/EP2017/060367 patent/WO2017191104A1/de not_active Ceased
-
2018
- 2018-10-23 IL IL262534A patent/IL262534B/en active IP Right Grant
- 2018-10-31 CL CL2018003107A patent/CL2018003107A1/es unknown
- 2018-11-02 CO CONC2018/0011948A patent/CO2018011948A2/es unknown
-
2020
- 2020-05-21 US US16/880,933 patent/US20200299271A1/en not_active Abandoned
-
2021
- 2021-06-14 JP JP2021098486A patent/JP2021143193A/ja not_active Withdrawn
- 2021-09-22 AU AU2021236502A patent/AU2021236502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018142264A3 (OSRAM) | 2020-08-19 |
| JP2021143193A (ja) | 2021-09-24 |
| AU2021236502A1 (en) | 2021-10-21 |
| JP2019514948A (ja) | 2019-06-06 |
| TWI755393B (zh) | 2022-02-21 |
| CO2018011948A2 (es) | 2018-11-22 |
| BR112018072528A2 (pt) | 2019-03-26 |
| MX391356B (es) | 2025-03-19 |
| KR20190003536A (ko) | 2019-01-09 |
| RU2018142264A (ru) | 2020-06-03 |
| CL2018003107A1 (es) | 2019-02-22 |
| US20190144431A1 (en) | 2019-05-16 |
| PE20190202A1 (es) | 2019-02-05 |
| WO2017191104A1 (de) | 2017-11-09 |
| AU2017259872B2 (en) | 2021-06-24 |
| TW201815782A (zh) | 2018-05-01 |
| AU2017259872A1 (en) | 2018-11-22 |
| US20200299271A1 (en) | 2020-09-24 |
| CA3022789A1 (en) | 2017-11-09 |
| UY37222A (es) | 2017-11-30 |
| CN109071500B (zh) | 2021-05-18 |
| RU2742885C2 (ru) | 2021-02-11 |
| MX2020010365A (es) | 2022-04-06 |
| MX2018013336A (es) | 2019-05-09 |
| IL262534A (en) | 2018-12-31 |
| MX379555B (es) | 2025-03-11 |
| CN109071500A (zh) | 2018-12-21 |
| EP3452467A1 (de) | 2019-03-13 |
| IL262534B (en) | 2021-04-29 |
| JP6921863B2 (ja) | 2021-08-18 |
| US10703742B2 (en) | 2020-07-07 |
| CN113105403A (zh) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809672YA (en) | Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives | |
| IL281196A (en) | Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate | |
| FI119548B (fi) | Apolipoproteiini B-synteesin estäjiä | |
| WO2008151437A1 (en) | Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system | |
| MY161482A (en) | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof | |
| WO2013042138A3 (en) | Process for preparation of triazole antifungal drug, its intermediates and polymorphs thereof | |
| RU2501791C2 (ru) | Производное триазола или его соль | |
| JP2017528504A5 (OSRAM) | ||
| JP2018519323A5 (OSRAM) | ||
| AR102487A1 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| TNSN07475A1 (fr) | Arylpyrazoles substitues destines a etre utilises contre des parasites | |
| US20230025510A1 (en) | Biaryl ether-type quinazoline derivatives | |
| NZ601316A (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | |
| PH12015502088A1 (en) | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | |
| JP2018511613A5 (OSRAM) | ||
| NZ701661A (en) | Method for the preparation of triazole compounds | |
| JP2014501232A5 (OSRAM) | ||
| MY198496A (en) | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives | |
| EP0871626A1 (en) | Novel triazolones as apolipoprotein-b synthesis inhibitors | |
| WO2007013096A8 (en) | Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole) | |
| EP3233824A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| IL291569A (en) | Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-4,2,1-triazol-3-amine | |
| WO2017070718A4 (en) | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1 | |
| AR076372A1 (es) | Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5 | |
| MX2017016042A (es) | Polimorfos de un compuesto de triazol que inhibe la pges-1. |